




31° Residential Course Modern Radiotherapy, innovative treatments and patients compliance

22- 23 November 2021

Scientific Coordinators: V. Valentini. M.A. Gambacorta, L. Indovina Honorary Presidents: C.A. Perez, N. Cellini



Sunday, 21 November 2021 (VIRTUAL)

16.00-16.05 Opening: course aims and modalities

16.05-16.15 What is considered compliance in the 20's?

Opening lecture (recorded)

16.15-16.40 Omics sciences and compliance to radiotherapy: is there a link?

Session 1 (live)

Metrics: Which compliance to be measured?

16.40-16.55	in radiotherapy randomized trials. The clinical perspective
16.55-17.10	in radiotherapy randomized trials. The dosimetric perspective
17.10-17.25	in technical innovations. The clinical perspective
17.25-17.40	in technical innovations. The dosimetric perspective

17.40-17.55 Question time

17.55-18.10 Break

Laboratory 1 (live)

18.10-18.55 PROM, PREM, App and IOT

Monday, 22 November 2021 (ONSITE and VIRTUAL)

Session 2 (live)

Metrics: which compliance is important for the patient undergoing radiotherapy?

09.00-09.15	Treatment compliance: patients vs clinicians perspectives
09.15-09.30	Treatment compliance: the psychological dimension in adults
09.30-09.45	Treatment compliance: priorities of care in elderly
09.45-10.00	Treatment compliance: the relational dimension in paediatrics

10.00-10.15 Question time

10.15-10.30 Break

Session 3 (live)

Actions: How to prevent and recover no-compliance?

10.30-10.45	Recommendations for no-compliance in radiotherapy treatments
10.45-11.00	Recommendations for no-compliance in chemoradiotherapy treaments
11.00-11.15	Innovation: AI and error prevention in RT
11.15-11.30	Innovation: nutritional aspects and microbioma

11.30-11.45 Question time

Lecture 1 (live or recorded)

11.45-12.10 Image guided radiotherapy technologies and treament compliance

Laboratory 2 (live)

12.10-12.55 Virtual coaching during interventional oncology treatments

12.55-14.30 Lunch Break

Session 4 (live)

Actions: Will innovation change compliance in radiotherapy treatments?

14.30-14.45	Innovation in image guided external beam radiotherapy
14.45-15.00	Innovation in adaptive external beam radiotherapy
15.00-15.15	Innovation in interventional radiotherapy
15.15-15.30	Innovation in particle therapies external bem radiotherapy

15.30-15.45 Question time

15.45-16.00 Break

Lecture 2 (live or recorded)

16.00-16.25 What is considered innovation in 20's radiotherapy?

Session 5 (live)

Actions: Big Data and AI: which contribution to compliance?

16.25-16.40	Big Data and AI for compliance monitoring clinical meaning
16.40-16.55	Big Data and AI for compliance prediction
16.55-17.10	Art and AI for patient's resilience

17.10-17.25 Question time

Lecture 3 (live or recorded)

17.45 -18.10 Compliance to treatments using stereotactic technolog
--

Tuesday, 23 November 2021 (ONSITE and VIRTUAL)

Lecture 4 (live or recorded)

compliance: a new	era?	pliance: a new era?
-------------------	------	---------------------

Session 6 (live)

Actions: Does drug innovation change compliance in combined treatments?

09.25-09.40	Monoclonal antibodies and small molecules
09.40-09.55	Immune check point blockade
09.55-10.10	Androgen pathway therapy

10.10-10.25 Question time

Lecture 5 (live or recorded)

10.25-10.50	Immunotherapy and radiotherapy: efficacy, innovative fractionations and
	compliance

10.50-11.05 Break

Session 6 (live)

Focus on: Prostate cancer innovation and compliance

11.05-11.25	Innovation, effectiveness and compliance in prostate cancer
11.25-11.40	Constraints and toxicity in standard treatments
11.40-11.55	Constraints and toxicity in innovative treatments

11.55-12.10 Question time

Session 7 (live)

Focus on: H&N cancer innovation and compliance

12.10-12.30	Innovation, effectiveness and compliance in H&N cancers
12.30-12.45	Constraints and toxicity in non conventional fractionations
12.45-13.00	Constraints and toxicity in innovative drug combinations

13.00-13.15 Question time

13.15-14.30 Lunch Break

Session 8 (live)

14.30-15.00 Sponsored lectures

Session 9 (live) Focus on: Lung cancer innovation and compliance

15.00-15.20	Innovation, effectiveness and compliance in lung cancers
15.20-15.35	Constraints and toxicity in standard treatments
15.35-15.50	Constraints and toxicity in innovative treatments

15.50-16.10 Question time

Lecture 6 (live or recorded)

16.10-16.30 Compliance between innovation and clinical experience: thoughts of an expert

16.30-16.45 Closing remarks

Wednesday, 24 November 2021 (VIRTUAL)

Lecture 7 (live or recorded)

15.30-15.55 Particle therapy and patient compliance

Session 8 (live)

Focus on: Breast cancer innovation and compliance

15.55-16.15	Innovation, effectiveness and compliance in breast cancer
16.15-16.30	Constraints and toxicity in standard treatments
16.30-16.45	Constraints and toxicity in non standard fractionation treatments

16.45-17.00 Question time

17.00-17.15 Break

Session 9 (live) Focus on: Anal cancer innovation and compliance

17.15-17.35	Innovation, effectiveness and compliance in anal cancer
17.35-17.50	Constraints and toxicity in standard treatments
17.50-18.05	Constraints and toxicity in interventional radiotherapy treatments

18.05-18.20 Question time

18.20 Closing remarks

Scientific Advisory Board Scientific Secretary: F.Miccichè, L. Boldrini, L. Tagliaferri, Educational committee Scientific organizing committee Meeting Secretary: Claudia DI BENEDETTO Gemelli ART – Fondazione Policlinico Universitario A.Gemelli IRCCS Largo A.Gemelli, 8 - 00168 ROMA, TEL 06-30155226 , FAX 06-35501928 e-mail: claudia.dibenedetto@policlinicogemelli.it